Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus α-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: Induction of CD80/86+ T cells indicates adverse outcome

Journal of Immunotherapy

Volumn 32, Issue 6, 2009, Pages 667-675

  Westermann, Jörg ^a   Hecker, Ann Christine ^a   Flörcken, Anne ^a   Dörken, Bernd ^a   Pezzutto, Antonio ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD80 86 positive T cells; Cytokine therapy; GM CSF; Renal cell cancer

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RIBOFLUOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC REACTION; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; CARDIOTOXICITY; CD80+ CD86+ T LYMPHOCYTE; CELL PROLIFERATION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; KIDNEY CANCER; LIVER TOXICITY; MALE; MENTAL DISEASE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIGENS, CD80; ANTIGENS, CD86; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, RENAL CELL; FEMALE; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 67651176263     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181a950e5     Document Type: Article

References (47)

1. Rathmell WM, Stadler WM, Rini BI. Rational therapeutic choices and strategies for patients with metastatic renal cancer. Am Soc Oncol Educ Book. 2008:192-198.
2. Fisher RI, Rosenberg SA, Fyfe G, et al. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1): 55-57.
3. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584-5591.
4. Medical Research Council Renal Cancer Collaborators. Interferon - a and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet. 1999;353: 14-17.
5. Pyrhönen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-2867.
6. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
7. Waller EK. The role of sargramostin (rhGM-CSF) as immunotherapy. Oncologist. 2008;12(suppl. 2):22-26.
8. Caux C, Dezutter-Dambuyant C, Schmitt D, et al. GM-CSF and TNF-a cooperate in the generation of dendritic Langer-hans cells. Nature. 1992;360:258-261.
9. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
10. Williams MA, Newland AC, Kelsey SM. Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy. Br J Haematol. 1997;98:960-968.
11. Atzpodien J, Kirchner H, Hanninen EL, et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer. 1993;29A(suppl 5): S6-S8.
12. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer. 2001;85:1130-1136.
13. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330-338.
14. Reiter Z, Ozes ON, Blatt LM, et al. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol. 1992;62:103-111.
15. Wadler S, Goldman M, Lyver A, et al. Phase-I trial of 5-fluorouracil and recombinant alpha2a-interferon in patients with advanced colorectal carcinoma. Cancer Res. 1990; 50:2056-2059.
16. Mitchell MS. Combinations of anticancer drugs and immuno-therapy. Cancer Immunol Immunother. 2003;52:686-692.
17. Schiller JH, Hank JA, Khorsand M, et al. Clinical and immunological effects of granulocyte-macrophage colony stimulating factor coadmistered with interleukin 2: a phase IB study. Clin Cancer Res. 1996;2:319-330.
18. De Gast GC, Klumpen HJ, Vyth-Dreese FA, et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res. 2000;6:1267-1272.
19. Westermann J, Reich G, Kopp J, et al. Granulocyte/macrophage-colony- stimulating-factor plus interleukin-2 plus inter-feron - a in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2001;49:613-620.
20. Schmidinger M, Steger G, Wenzel C, et al. Sequential administration of interferon-gamma, GM-CSF and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial. J Immunother. 2001;24:257-262.
21. Tate J, Olencki T, Finke J, et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal cell carcinoma: clinical and laboratory effects. Ann Oncol. 2001; 12:655-659.
22. Smith JW, Kurt RA, Baher AG, et al. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma. J Immunother. 2003; 26:130-138.
23. Lissoni P, Mengo S, Bucovec R, et al. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients. In Vivo. 2003;17:73-75.
24. Verra N, Jansen R, Groenewegen G, et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-a in patients with progressive metastatic renal cell carcinoma. Br J Cancer. 2003;88:1346-1351.
25. Koulova L, Novik Y, Caliendo G, et al. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma. J Immunother. 2005;28: 576-581.
26. Correale P, Cusi MG, Tsang KY, et al. Chemo-Immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX4 followed by subcutaneous granulocyte macrophage colony stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005;23:8950-8958.
27. Correale P, Tagliaferri P, Fioravanti A, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+ FOLFOX followed by subcutaneous granulocyte macrophage colony stimulating factor and aldesleukin (GOLFIG-1 trial). Clin Cancer Res. 2008;14:4192-4199.
28. Wyss-Coray T, Mauri-Hellweg D, Baumann K, et al. The B7 adhesion molecule is expressed on activated human T cells: functional involvement in T-T cell interactions. Eur J Immunol. 1993;23:2175-2180.
29. Azuma M, Yssel H, Phillips JH, et al. Functional expression of B7/BB1 on activated lymphocytes. J Exp Med. 1993;177: 845-850.
30. Jeannin P, Herbault N, Delneste Y. Human effector memory T cells express CD86: a functional role in naive T cell priming. J Immunol. 1999;162:2044-2048.
31. Sansom DM, Hall ND. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur J Immunol. 1993;23:295-298.
32. Abe K, Takasaki Y, Ushiyama C. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematodes. J Clin Immunol. 1999;19:58-66.
33. Barnaba V, Watts C, de Boer M, et al. Professional presentation of antigen by activated human T cells. Eur J Immunol. 1994;24:71-75.
34. Ferlazzo G, Semino C, Meta M, et al. T lymphocytes express B7 family molecules following interaction with dendritic cells and acquire bystander costimulatory properties. Eur J Immunol. 2002;32:3092-3101.
35. Moosig F, Csernok E, Wang G, et al. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential upregulation of ist ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol. 1998;114: 113-118.
36. Thurnher M, Radmayr C, Hobisch A. Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T cell expansion by T-T cell costimulation. Int J Cancer. 2005;62:559-564.
37. Taylor PA, Lees CJ, Fournier S, et al. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions (corrections). J Immunol. 2004;172:34-39.
38. Paust S, Lu L, Mc Carty N, et al. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A. 2004;101:10398-10403.
39. Paust S, Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev. 2005;204:195-207.
40. Wos E, Olencki T, Tuason L, et al. Phase II trial of subcutaneously administered granulocyte-macrophage colony stimulating factor in patients with metastatic renal cell carcinoma. Cancer. 1996;77:1149-1153.
41. Rini BI, Stadler WM, Spielberger RT, et al. Granulocyte-macrophage colony stimulating factor in metastatic renal cell carcinoma. Cancer. 1998;82:1352-1358.
42. Amato RJ, Malya RM, Rawat A. Phase-II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony- stimulating-factor in patients with meta-static renal cell carcinoma. Am J Clin Oncol. 2008;31:237-243.
43. Quemeneur L, Gerland LM, Flacher M, et al. Differential control of cell cycle, proliferation and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol. 2003;170:4986-4995.
44. Quemeneur L, Beloeil L, Michallet MC. Restriction of de novo nucleotide biosythesis interferes with clonal expansion and differentiation into effector and memory CD8T cells. J Immunol. 2004;173:4945-4952.
45. Markasz L, Skribek H, Uhlin M, et al. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T lymphocytes. J Immunother. 2008;31:283-293.
46. Eisenthal A, Eytan K, Brazowski E, et al. Effects of 5-fluorouracil on human mitogen-activated peripheral blood lymphocytes from healthy individuals. Anticancer Res. 2008; 28:3785-3791.
47. Larkin JM, Gore ME. The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil versus interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress. Clin Oncol. 2008; 17:319-321.